The difference between Brivaracetam tablets and Brivaracetam

Brivaracetam/Brivaracetam (Brivaracetam) and Brivaracetam are actually different names for the same drug. Brivaracetam is its international nonproprietary name (INN), and "Brivaracetam" is the transliteration of its Chinese name. It is a new type of anti-epileptic drug, which is a pyrroleacetamide derivative. It is structurally similar to levetiracetam, but has a stronger affinity for synaptic vesicle protein 2A (SV2A) at the molecular level, has faster onset of action and better tolerance. The drug was developed by the Belgian company UCB Pharmaceuticals under the trade name Briviact. It was initially approved for marketing in Europe and the United States, and was subsequently promoted in many countries including Japan and South Korea.

Brivaracetam is mainly used to treat partial seizures of epilepsy (focal epilepsy), either alone or in combination with other anti-epileptic drugs. Its mechanism of action is to regulate the release of synaptic vesicles by highly selectively binding to the SV2A protein on the neuronal membrane, thereby stabilizing the conduction of nerve signals and reducing the frequency of epileptic seizures. Compared with earlier drugs, brivaracetam's pharmacokinetics include rapid absorption, high bioavailability, relatively stable liver metabolism, less interference with the central nervous system, and milder side effects.

In terms of dosage forms, Brivaracetam provides tablets, oral solutions, injections and other forms to facilitate the use scenarios of different patients. The dose is generally adjusted based on individual response, with a common starting dose being 50–100 mg daily. It should be noted that regardless of the difference in name, the pharmacological activity and indications are exactly the same. Patients only need to confirm that the active ingredient of the drug is Brivaracetam when purchasing or using it. At present, the domestic market is not generally available, and imported original drugs are relatively expensive, while some overseas channels provide generic versions at relatively affordable prices.

Overall, brivaracetam is one of the important new drugs in the current field of epilepsy treatment, and its stability and safety have been widely recognized internationally.

Reference materials:https://www.briviact.com/